NAD+ vs P-21 Peptide
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential to cellular metabolism, DNA repair, and mitochondrial function. Levels decline with age. Research focuses on restoring NAD+ through precursors (NMN, NR) or direct IV/subcutaneous administration to support longevity and energy metabolism.
Full profileP-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profile| NAD+ | P-21 Peptide | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Nicotinamide Adenine Dinucleotide, NAD, NAD+ precursor | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide |
| Evidence | Preclinical only | Preclinical only |
| Dosing range | 250mg–1000mg mg, daily (oral precursors) or weekly/monthly (IV/SubQ) | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) |
| Administration | Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal | Intranasal, Subcutaneous injection |
| Key side effects | Flushing (especially IV), Chest tightness during rapid IV infusion, Nausea, Fatigue (transient, day of infusion) | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: NAD+ — Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal; P-21 Peptide — Intranasal, Subcutaneous injection.
- Dosing units differ: NAD+ is dosed in mg, P-21 Peptide in mcg — they operate at different scales.
- Frequency: NAD+ is typically daily (oral precursors) or weekly/monthly (IV/SubQ); P-21 Peptide is daily or every other day (intranasal or SC).
How each works
NAD+
NAD+ is required for over 500 enzymatic reactions including those catalyzed by sirtuins (longevity-associated proteins) and PARPs (DNA repair enzymes). Rodent studies consistently show that restoring NAD+ levels reverses aspects of metabolic aging. Human trials with NAD+ precursors (NMN, NR) show improved muscle function, insulin sensitivity, and mitochondrial capacity in older adults.
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.